ABPI (Association of the British Pharmaceutical Industry)

The voice of the UK pharmaceutical industry since 1891, ABPI (Association of the British Pharmaceutical Industry) represents companies that research, develop and manufacture medicines for patients and the NHS. Its membership spans the full breadth of the sector, from global research-based manufacturers to smaller innovative biotechnology firms, collectively accounting for a significant share of the UK's life sciences economy.

The association works at the intersection of industry, government, and healthcare, engaging with the NHS, the Medicines and Healthcare products Regulatory Agency (MHRA), and policymakers across Westminster and the devolved nations. A central part of this role involves shaping the environment for medicines access and pricing, including the Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), which governs how the NHS manages its branded medicines bill.

Beyond policy, the ABPI publishes widely referenced industry data, workforce reports, and clinical pipeline analyses that serve as standard references across the sector. It also sets the ABPI Code of Practice, the self-regulatory framework governing how member companies promote medicines to healthcare professionals in the UK, administered independently by the Prescription Medicines Code of Practice Authority (PMCPA).

The organisation plays a coordinating role in advancing the UK's broader life sciences ambitions, contributing to government strategies around clinical trials, R&D investment, and supply chain resilience. Its annual Figures report is a benchmark publication for understanding the scale and direction of pharmaceutical activity in Britain.

Further information is available at abpi.org.uk.